Market capitalization | $1.38b |
Enterprise Value | $1.15b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.99 |
P/S ratio (TTM) P/S ratio | 10.75 |
P/B ratio (TTM) P/B ratio | 4.97 |
Revenue growth (TTM) Revenue growth | 67.51% |
Revenue (TTM) Revenue | $128.29m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a RxSight Inc forecast:
10 Analysts have issued a RxSight Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 128 128 |
68%
68%
|
|
Gross Profit | 88 88 |
102%
102%
|
|
EBITDA | -35 -35 |
30%
30%
|
EBIT (Operating Income) EBIT | -39 -39 |
28%
28%
|
Net Profit | -31 -31 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.
Head office | United States |
CEO | Ronald Kurtz |
Employees | 374 |
Founded | 1997 |
Website | rxsight.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.